The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Biotech company Paradigm Pharmaceuticals has launched a $77.9 million capital raise.

The raise will invest in further clinical research, drug development and hiring US-based million staff. $51.6 million of the raise will comprise of placement to investors across Australia.

This placement will consist of an issue of 34,370,099 shares. The remaining $26.3m will go to an accelerated non-renounceable entitlement offer underwritten by Bell Potter securities.

The entitlement offer will consist of 17,537,431 shares at A$1.50 per share. This raise will put the company in a strong position to negotiate commercial transactions.

The company is currently researching osteoarthritis (OA) and mucopolysaccharidosis (MPS) treatment. MPS is a rare condition where the patient is unable to break down sugar molecules throughout the body.

Both OA and MPS research projects are currently in stage three. Current OA research shows possible remission of disease and reduction of pain.

Please see the announcement attached

PAR by the numbers
More From The Market Herald

DigitalX Bitcoin Fund jumps 5.3pc in November

DigitalX (ASX:DCC) has released its monthly update to shareholders, revealing the DigitalX Bitcoin Fund increased 5.3…

Cynata Therapeutics receives approval to launch phase two trial of CYP-001 in Turkey

Cell therapy company, Cynata Therapeutics (ASX:CYP) has received regulatory and ethics approval to commence a phase…

Little Green Pharma positions itself for growth in France’s emerging medicinal cannabis market

Little Green Pharma (ASX:LGP) is primed for substantial growth after a major amendment to the French…

PolyNovo posts $8m sales month and $9m revenue month for November

Disruptive medical device company PolyNovo (ASX:PNV) has announced record monthly sales of $8.8 million for November…